ADMA Biologics Inc (ADMA)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 51.48% | 34.44% | 22.89% | 1.45% | -45.17% |
| Operating profit margin | 32.59% | 8.38% | -25.55% | -72.12% | -153.75% |
| Pretax margin | 29.48% | -10.94% | -42.77% | -88.52% | -179.41% |
| Net profit margin | 46.35% | -10.94% | -42.77% | -88.52% | -179.41% |
ADMA Biologics Inc's profitability ratios have shown a significant improvement over the years based on the provided data. The gross profit margin, which measures the percentage of revenue that exceeds the cost of goods sold, has seen a remarkable increase from negative percentages in 2020 and 2021 to a healthy 51.48% by December 31, 2024, indicating better cost management and pricing strategies.
The operating profit margin, representing how much of each dollar of revenue translates into profit after accounting for operating expenses, has also shown a positive trend. It has progressed from negative figures in 2020 and 2021 to a robust 32.59% by December 31, 2024, reflecting improved operational efficiency and cost control measures.
Similarly, the pretax margin, which demonstrates the company's ability to generate profit before taxes, has experienced a notable turnaround. Starting from significant negative percentages in 2020 and 2021, ADMA Biologics Inc managed to achieve a positive margin of 29.48% by December 31, 2024, indicating enhanced financial performance and profitability.
Moreover, the net profit margin, which reveals how much of each dollar of revenue translates into profit after all expenses have been deducted, has seen a remarkable recovery. After facing negative margins in the previous years, the company achieved a strong net profit margin of 46.35% by December 31, 2024, signaling improved bottom-line performance and potential for sustainable profitability in the future.
Overall, ADMA Biologics Inc has demonstrated substantial progress in its profitability ratios over the years, reflecting effective cost management, operational efficiency, and financial performance enhancements.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 28.44% | 6.57% | -11.30% | -21.13% | -31.26% |
| Return on assets (ROA) | 40.45% | -8.58% | -18.91% | -25.94% | -36.48% |
| Return on total capital | 32.98% | -1.21% | -15.82% | -24.82% | -35.19% |
| Return on equity (ROE) | 56.64% | -20.89% | -43.37% | -50.75% | -85.84% |
ADMA Biologics Inc has shown a consistent improvement in its profitability ratios over the years. The Operating Return on Assets (Operating ROA) increased from negative values of -31.26% in 2020 to a positive value of 28.44% in 2024, indicating the company's ability to generate operating profits from its assets.
Similarly, the Return on Assets (ROA) also improved from -36.48% in 2020 to 40.45% in 2024, reflecting a positive trend in overall profitability relative to its total assets.
The Return on Total Capital also exhibited a positive trajectory, rising from -35.19% in 2020 to 32.98% in 2024. This indicates the efficiency of ADMA Biologics Inc in generating returns from both debt and equity capital invested in the business.
Lastly, the Return on Equity (ROE) showed a significant turnaround, improving from -85.84% in 2020 to a notable 56.64% in 2024, demonstrating the company's ability to generate higher returns for its equity shareholders.
Overall, the profitability ratios of ADMA Biologics Inc have displayed a positive trend over the years, reflecting improved operational efficiency and financial performance.